ArticleJournal of neuro-oncology2026
Long term outcomes and predictors of recurrence in central neurocytomas: a 35-year multi-institutional experience.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCentral neurocytomas (CNs) are rare, WHO grade 2 brain tumors that have relatively high recurrence rates following resection. The present collaboration between Northwestern University and the Mayo Clinic describes long-term outcomes of CN as it relates to potential prognostic variables that entail recurrence risk, such as RT timing, tumor proliferation index (Ki-67), and age at diagnosis.
methodsPatients established between 1990 and 2025 with a tissue diagnosis of CN were reviewed. Recurrence free survival (RFS) and overall survival (OS) were calculated according to the Kaplan Meier-method. Multivariate cox regression analysis was performed with pre-planned variables.
resultsFifty-one patients with CN with a median age of 26 years and 9.7 years median follow-up were included. OS at 10 years for the cohort was 94%. Without adjuvant RT, 5-year RFS for post-GTR was 61% versus 46% for post-STR (P value = 0.18). Multivariate analysis found omission of adjuvant RT (HR: 9.0, P = 0.003), subtotal resection (HR:5.7, P = 0.017), younger age at diagnosis (HR3.1, P = 0.002), and higher Ki-67 (HR 1.13, P = 0.017) were associated with worse RFS. Salvage RT after first recurrence (n = 17) had a 5-year RFS of 83%, with a median follow-up of 4.8 years.
conclusionsWe report one of the largest and most comprehensive cohorts of CN with long-term follow-up. Contrary to previous reports, recurrences were frequent after GTR. Higher Ki-67 and age at diagnosis were associated with worse RFS in our cohort. Salvage RT at recurrence achieved durable long-term tumor control, and 10-year mortality was low.
Indexed as
Identifiers
42875684What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.